New drug combo may make inoperable lung cancer removable
NCT ID NCT03872661
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving a combination of drugs (IBI308, bevacizumab, pemetrexed, and carboplatin) before surgery can shrink stage III non-small cell lung cancer enough to allow surgical removal. The goal is to see how many people can then have surgery. The study includes 36 adults with unresectable stage III lung cancer who do not have certain gene mutations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER STAGE III are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New immunotherapy combo aims to improve lung cancer outcomes
- New combo aims to turn untreatable lung tumors into surgical candidates
- New hope for hard-to-treat lung cancer: targeted drugs before surgery
- New drug combo aims to shrink lung tumors enough for surgery
- Triple threat: new combo aims to stop lung cancer in its tracks
- Could an arthritis drug boost chemo for lung cancer?